Daniel Goldstein MD

1.8K posts

Daniel Goldstein MD banner
Daniel Goldstein MD

Daniel Goldstein MD

@drdgoldstein

Founding Director, Center for Cancer Economics, Professor of Oncology @Rabinmedical_. @TelAvivUni.

Israel Katılım Temmuz 2011
61 Takip Edilen1.5K Takipçiler
Daniel Goldstein MD retweetledi
Dr Amol Akhade
Dr Amol Akhade@SuyogCancer·
Happy To Share Our Paper published In Lancet Oncology. It is joint venture between myself and @ManjuSengar7 and Dr Roni Levin And @drdgoldstein from Israel 🇮🇱. We closely looked at Subcut IO drugs approvals and discuss that even though sub cut formulations are more convenient they may actually prolong patents and may delay entry of Biosimilar IO drugs . Wolf 🐺 in Sheep 🐑 clothing. Classic essay in Pharmaco Economics 🙂 @TheLancetOncol @Larvol @brunolarvol @OncBrothers @MedwatchKate thelancet.com/journals/lanon…
English
3
14
72
7.8K
Daniel Goldstein MD
Daniel Goldstein MD@drdgoldstein·
@GalMarkel I also express gratitude for the opportunity of the past 4 years working within the headquarters of Clalit, Israel’s largest HMO. It was an unparalleled opportunity to see the inner workings of policy decision making in the health system. Looking forward to this new chapter. end
English
2
0
0
244
Daniel Goldstein MD
Daniel Goldstein MD@drdgoldstein·
I will continue my clinical work as a GU oncologist. I have great thanks to the Director of the Davidoff Center, @GalMarkel, and my long-time colleague and friend Dr Eli Rosenbaum who have provided great support in making this happen, and who share and appreciate the vision. 2/n
English
1
0
1
275
Daniel Goldstein MD
Daniel Goldstein MD@drdgoldstein·
Some personal news…. I’m delighted to announce that I’m returning full time to the Davidoff center of Rabin Medical Center. I will be opening the Center for Health Economics and Medical Decision Making, which will focus on Education, Research and Consultancy. 1/n
English
5
3
26
2.7K
Daniel Goldstein MD
Daniel Goldstein MD@drdgoldstein·
Really great pleasure to help to run this workshop in Hong Kong. Thanks to Vivian Lee for amazing organization, and to @herbloong for being a great host to satisfy my foodie instincts!
Herbert Loong, MBBS, FASCO@herbloong

Thanks @drdgoldstein for coming all the way from 🇮🇱 to 🇭🇰 to share insights and experiences in #pharmacoeconomics. Organised by #ProfVivianLee and colleagues of @cuhkpharmacy Very engaged workshop together with stakeholders from #academia, #industry, #patientsrepresentatives and the #HospitalAuthority @CUHKMedicine @hkumed

English
0
0
5
516
Daniel Goldstein MD retweetledi
Daniel Goldstein MD retweetledi
Dr Deme Karikios
Dr Deme Karikios@DKarikios·
If you are an oncologist/trainee interested in the Common Sense Oncology movement you can contribute here @csoncol #commonsenseoncology:
Dr Deme Karikios tweet media
English
0
7
20
1.4K
Daniel Goldstein MD
Daniel Goldstein MD@drdgoldstein·
@ajumathew_ Hey Aju. The issue of CDK4/6 is complex and nuanced. There is definitely opportunity for class effect exploitation, but not in the adjuvant setting. I would argue that the data are weak to support any cdk4/6 in the adjuvant setting. pubmed.ncbi.nlm.nih.gov/37146621/
English
1
0
1
67
Aju Mathew
Aju Mathew@ajumathew_·
@drdgoldstein Hi Dan, Congratulations. I read the paper. I didn't understand the point of discussing class effect of CDK4/6i. Were you suggesting that, for instance, in adjuvant therapy for breast, all CDK4/6i can be used interchangeably? Or, for that matter, in metastatic disease?
Aju Mathew tweet media
English
1
0
0
98